You are here

Phase 3 Trial Evaluates Rebamipide Ophthalmic Suspension in Patients With Dry Eye Syndrome

Dry eye is one of the most common disorders treated by ophthalmologists in their daily practices. An estimated 25 million Americans and 370 million people worldwide have the disorder.

Rebamipide ophthalmic suspension increases the level of mucin in the tear film covering the conjunctiva and cornea. In January 2012, the drug was launched for the treatment of dry eye syndrome in Japan as Mucosta ophthalmic suspension UD2%.

The new phase III study will evaluate the efficacy and safety of 2% rebamipide ophthalmic suspension in approximately 560 subjects with dry eye syndrome. The trial is expected to be completed by the end of 2013. Acucela and Otsuka entered into an agreement on September 4, 2008 to co-develop rebamipide ophthalmic suspension for the treatment of dry eye syndrome in the U.S. Acucela will lead the regulatory strategy to gain approval for the product in this country.

Read the full article on the Reuters Web site.

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Zip Device Faster to Apply, Minimizes Scarring
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen